Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Inclusion Criteria: * Adult subjects (18-75 years of age) with either hepatitis e antigen (HBeAg) positive or HBeAg negative chronic HBV prior to transplant * Willing and able to provide written informed consent * Subjects with detectable antibody to hepatitis B surface antigen performed by a local laboratory result within 30 days of screening * Subjects must have been stable and may not have had 2 or more of the following laboratory parameters associated with decompensated liver disease: conjugated bilirubin \> 1.5 x the upper limit of the normal range (ULN), prothrombin time \> 1.5 x ULN, platelets \< 60,000/mm\^3, serum albumin \< 3.0 g/dL * Must have had at least 12 weeks of center-specific prophylactic therapy including hepatitis B immunoglobulin (HBIg) posttransplant * Calculated creatinine clearance ≥ 40 mL/min using the Cockcroft-Gault equation * No significant evidence of ongoing deterioration of renal function * Negative serum beta-human chorionic gonadotropin (for females of childbearing potential only) Exclusion Criteria: * Subjects with HBV recurrence, ie, confirmed HBV DNA ≥ 400 copies/mL, following liver transplant * Pregnant women, women who were breast feeding or who believed they may have wished to become pregnant during the course of the study * Males and females of reproductive potential who were unwilling to use an effective method of contraception during the study and for at least 30 days from the date of last dose of study drug * Evidence of hepatocellular carcinoma (HCC), eg, alpha-fetoprotein \> 50 ng/mL, or by any other standard of care measure or presence of multifocal HCC at the time of transplantation if transplantation was within 144 weeks of screening * Prior TDF or FTC/TDF experience post-transplant or \> 12 months treatment with TDF or FTC/TDF treatment pretransplant * Coinfection with hepatitis C virus (by serology), HIV, or hepatitis D virus pretransplant or at screening * Significant renal, cardiovascular, pulmonary, or neurological disease * Known hypersensitivity to the study drugs, the metabolites, or formulation excipients * Were likely to receive systemic drugs with nephrotoxic potential, except immunosuppressive agents (eg, cyclosporine, tacrolimus), during the course of the study * History of variceal bleeding or hepatic encephalopathy following orthotopic liver transplantation